Your browser doesn't support javascript.
loading
Effectiveness of vero cell inactivated vaccine against severe acute respiratory infections (SARI) in Sibu, Malaysia: A retrospective test-negative design.
Toh, Teck-Hock; Qi, Yang-Yang; Yong, Sook-Min; Lee, Jeffrey Soon-Yit; Liyana, Nur Fatin; See, Raymond Yon-Han; Teh, Jo-Hun; Toh, Aw-Zien; Naing, Lin; Dahian, Kamilah; Liew, Jun-Wei; Mose, Caisha Nivenia; Yong, Malvina Zi-Qing; Ling, Ngiik-Jing; Chua, Diana Wang-Sing; Ling, Wee-Wei; Thirunavukkarasu, Nanthakumar; Suhaili, Mohd Raili; Xia, Jie-Lai; Clemens, John; Wang, Xuan-Yi.
Afiliação
  • Toh TH; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Qi YY; Faculty of Medicine, SEGi University, Kota Damansara, Malaysia.
  • Yong SM; Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China.
  • Lee JS; Key Laboratory of Medical Molecular Virology of MoE & MoH, and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
  • Liyana NF; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • See RY; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Teh JH; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Toh AZ; Divisional Health Office, Ministry of Health Malaysia, Sibu, Malaysia.
  • Naing L; Divisional Health Office, Ministry of Health Malaysia, Sibu, Malaysia.
  • Dahian K; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Liew JW; PAPRSB Institute of Health Sciences, University Brunei Darussalam, Bandar Seri Begawan, Brunei Darussalam.
  • Mose CN; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Yong MZ; Medical Department, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Ling NJ; Emergency & Trauma Department, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Chua DW; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Ling WW; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Thirunavukkarasu N; Clinical Research Centre, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Suhaili MR; Emergency & Trauma Department, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Xia JL; Director Office, Sibu Hospital, Ministry of Health Malaysia, Sibu, Malaysia.
  • Clemens J; Faculty of Medicine, SEGi University, Kota Damansara, Malaysia.
  • Wang XY; Xijing Hospital, Xi'an, China.
Hum Vaccin Immunother ; 19(1): 2167438, 2023 12 31.
Article em En | MEDLINE | ID: mdl-36705277
ABSTRACT
The effectiveness of the vero cell inactivated vaccine (CoronaVac®) against severe acute respiratory infection ( SARI) caused by SARS-CoV-2 in the real world was assessed. A matched test-negative case-control design was employed using the web-based national information system, as well as the hospitalization dataset in Sibu Hospital. Vaccine effectiveness was measured by conditional logistic regression with adjustment for gender, underlying comorbidity, smoking status, and education level. Between 15 March and 30 September 2021, 838 eligible SARI patients were identified from the hospitalization records. Vaccine effectiveness was 42.4% (95% confidence interval [CI] -28.3 to 74.1) for partial vaccination (after receiving the first dose to 14 days after receiving the second dose), and 76.5% (95% CI 45.6 to 89.8) for complete vaccination (at 15 days or more after receiving the second dose). This analysis indicated that two doses of CoronaVac® vaccine provided efficacious protection against SARI caused by SARS-CoV-2 in the short term. However, the duration of protection, and performance against new variants need to be studied continuously.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia / Vacinas / COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Humans País como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia / Vacinas / COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Animals / Humans País como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article